Tremfya®(古塞库单抗)成为首个且唯一一款在溃疡性结肠炎治疗中通过全皮下注射方案在48周内实现持续临床和内镜检查疗效的IL-23抑制剂。
Tremfya®(古塞库单抗)成为首个且唯一一款在溃疡性结肠炎治疗中通过全皮下注射方案在48周内实现持续临床和内镜检查疗效的IL-23抑制剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.